Context: Vitamin D "insufficiency" and "deficiency" are defined as serum 25-hydroxyvitamin D [25(OH)D] levels ,75 and ,30 nmol/L, respectively. We aimed to determine whether these values signal hypocalcemia and hypophosphatemia, secondary hyperparathyroidism, high bone remodeling, low areal bone mineral density (aBMD), microstructural deterioration, or reduced matrix mineralization density (MMD) and so suggest whether bone fragility is present.
itamin D deficiency and insufficiency are defined as a serum 25-hydroxyvitamin D [25(OH)D] concentration of ,30 and ,75 nmol/L, respectively (1, 2) . If these thresholds accurately signal bone disease, then approximately 4% of individuals have vitamin D "deficiency" and 75% have "insufficiency" (3) . Under these circumstances, these thresholds should identify persons with abnormalities in the biochemical pathway leading to these bone diseases and signal the presence of osteomalacia, osteoporosis, or both.
A deficient or insufficient state is implied when serum concentrations of 25(OH)D below these nominal thresholds are associated with deficits in the active metabolite, 1,25-dihydroxyvitamin D. During the evolution of vitamin D deficiency, an initial reduction in serum calcium is compensated for by secondary hyperparathyroidism, which increases bone remodeling and thereby maintains serum calcium in the normal range. This occurs at the price of the higher parathyroid hormone (PTH) and more rapid bone remodeling; this replaces older, more fully mineralized bone with younger bone, which initially undergoes normal primary mineralization. However, matrix mineral density is lowered because secondary mineralization proceeds slowly, over many months (4) (5) (6) (7) .
If remodeling is unbalanced (i.e., less bone is deposited than resorbed), the rapid unbalanced remodeling causes microstructural deterioration (high cortical porosity, reduced trabecular number and thickness). With time, the newly deposited bone fails to undergo primary mineralization because of a decrease in the calcium 3 phosphate product as the PTH produces phosphaturia, leading to osteomalacia. The thresholds for an "insufficiency" state were not based on quantitative biochemical or structural criteria but are derived according to intakes of vitamin D ensuring that 95% of the population will have 25(OH)D levels above a nominal threshold level (8) . The gold standard to diagnose osteomalacia is based on increased osteoid thickness found in bone biopsy samples (9) . This is rarely performed because of cost, patient discomfort, and limited availability of the procedure.
The aim of this study was to examine whether the current nominal thresholds used to define vitamin D "deficiency" and "insufficiency" identify persons with biochemical or morphologic evidence of impending or prevalent bone disease and whether the proportion of persons with biochemical or morphologic abnormalities increased as the levels of serum 25(OH)D diminished.
Methods

Participants
We studied two cohorts. The first included 11,855 patients: 8777 women and 3078 men investigated for vitamin D nutritional health with blood samples collected and assayed by Melbourne Pathology during a 5-year period (2007 to 2011). We excluded persons aged younger than 20 years, patients with hypercalcemia (defined as corrected serum calcium .2.6 mmol/L), chronic kidney disease (defined as an estimated glomerular filtration rate ,60 mL/min per 1.73 m 2 , calculated according to the Chronic Kidney Disease Improved Prediction Equations method), and a 25(OH)D level .180 nmol/L. The second cohort included 150 patients from Austin Health: 120 women and 30 men. A subset of this cohort had bone turnover markers (n = 56 women), areal bone mineral density (aBMD; n = 148; 119 women and 29 men) and volumetric BMD (vBMD) (n = 58; 54 women and 4 men) measured. We excluded patients with thyroid disease, primary hyperparathyroidism, bony metastases, or chronic kidney disease and those receiving osteoporosis treatment.
Measurements
In the first cohort, serum 25(OH)D was measured by using the DiaSorin Liaison platform; PTH, calcium (corrected for albumin), phosphate, alkaline phosphatase (ALP), g-glutamyl transferase, and creatinine were measured by using a Roche platform. The coefficient of variation for the 25(OH)D Liaison platform was 13% at 15 nmol/L. In the second cohort, serum 25(OH)D, PTH, calcium (corrected for albumin), and creatinine were measured by using a Roche platform. The coefficient of variation for the 25(OH)D Roche platform was 22% at 14 nmol/L. The Roche and Liaison 25(OH)D assays had good correlation (r 2 = 0.93; slope = 1.05; intercept = 0). A subgroup had measurements of serum C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N-terminal propeptide (P1NP) by using a Roche platform, the aBMD of the lumbar spine and femoral neck was measured by using dual x-ray absorptiometry (GE Lunar Prodigy, Madison, WI).
Images of the distal radius were acquired by using highresolution peripheral micro-computed tomography (Xtreme CT, Scanco Medical AG, Brüttisellen, Switzerland) and were processed by using StrAx1.0 (StraxCorp, Melbourne, Australia) (10). StrAx1.0 segments bone from background and cortical from trabecular compartments. The total cortex is further segmented into its compact-appearing and transitional zones so that the porosity and the fragmented (trabecularized) cortex are correctly assigned to the transitional zone rather than to the medullary compartment, which would otherwise underestimate cortical porosity and overestimate trabecular density (11) . Porosity of the compact-appearing and transitional zone and the trabecular density were quantified. Matrix mineralization density (MMD) was quantified as the mean attenuation of voxels unlikely to contain voids (pores). These are voxels with attenuation photons between 80% and 100% of the photon attenuation produced by fully mineralized bone matrix (1200 mgHA/mL) (11).
Statistical analyses
Summary statistics for sample characteristics are presented as mean and standard deviation. Piecewise linear regression was initially used to find a breakpoint in the relationship between 25(OH)D and PTH, alkaline phosphatase, calcium, and phosphate for the Melbourne Pathology data. Robust regression was then used to refit the data by using the breakpoint found from the piecewise linear regression, adjusted for age. This method was also applied to the Austin Health data. P values were computed by using the nonparametric Kruskal-Wallis test to compare equality of the median between the quartiles of 25(OH)D. Seasonal adjustments were made to assess the effect of blood collection month on 25(OH)D, PTH, and associations with bone parameters. To examine the seasonal effect on the serum measurements, we used penalized regression splines method, a nonparametric regression approach, to smooth the relationship between each serum measurement and date of the year when the serum was collected. The method was implemented in the package mgcv within the R computing software (12, 13) . All analyses were carried out using Stata software, version 13 (Stata Corp., College Station, TX).
Results
Study participants' characteristics are shown in Table 1 . There was a positive association between serum 25(OH)D and serum calcium and serum phosphate: the lower the serum 25(OH)D, the lower the serum calcium and serum phosphate [ Fig. 1(a) and 1(b) ]. For serum calcium, the breakpoint occurred at a serum 25(OH)D level of 30 nmol/L. The association between serum calcium and 25(OH)D differed above and below the breakpoint (P , 0.001). No breakpoint was detected for serum phosphate (Table 2) . Among participants with a serum 25(OH)D level of #30 nmol/L, 6.1% had hypocalcemia and 3.4% had hypophosphatemia.
The frequency of blood sampling was evenly distributed through the seasons and did not differ between the two cohorts. The proportion of blood sampling for spring, summer, autumn, and winter were 28%, 22%, 25%, and 25% respectively, in the larger cohort and 34%, 20%, 22%, 24% in the smaller cohort. There was seasonal and highest mean serum PTH concentration (5.6 pmol/L) were found in samples drawn in spring (Fig. 2) . Serum PTH and ALP were negatively associated with serum 25(OH)D, with evidence of a breakpoint at serum 25(OH)D level of 31 nmol/L (P , 0.001). The association between serum PTH, ALP, and 25(OH)D differed above and below the breakpoint (Table 2 ). In the 1439 participants with serum 25(OH)D of #30 nmol/L, mean PTH (6.7 pmol/L) was within the reference interval and two thirds (947 participants) did not have an elevated PTH [ Fig. 1(c) ]. Moreover, there was no detectable nadir or plateau above 75 nmol/L: the higher the serum 25(OH)D, the lower the serum PTH. Only 6.1% of patients with a 25(OH)D level of #30 nmol/L had a raised ALP level [ Fig. 1(d) ].
There was no detectable association between 25(OH)D and CTX (P = 0.13), P1NP (P = 0.95), aBMD at the lumbar spine (P = 0.38) or femoral neck (P = 0.20), trabecular vBMD (P = 0.96), matrix mineralization (P = 0.74), and cortical (P = 0.71) or transitional (P = 0.75) zone porosity at the distal radius (Fig. 3) . No significant association was found between PTH and the preceding parameters (Table 3) . When 25(OH)D was assessed as a continuous variable or as a categorical variable with thresholds of ,50 nmol/L, 50 to 75 nmol/L, and .75 nmol/L, no significant difference was seen in biochemical or bone parameters (Supplemental Table 1 ). In particular, no difference was found in a comparison of participants with 25(OH)D above or below the threshold of 75 nmol/L (Supplemental Table 2 ). There was no association between bone mineral density (BMD) or microstructure comparing quartiles of 25(OH)D, nor was there a difference comparing the median value of the four quartiles. Seasonal adjustment did not alter the results. However, this could be done only in the smaller cohort, and we lacked the power to detect a biologically important difference of 0.5 standard deviation between the highest and lowest quartiles.
Discussion
We report independent associations between concentrations of serum 25(OH)D and serum calcium, phosphate, PTH, and ALP. The association between a declining serum 25(OH)D level and an increasing serum PTH level is well documented (14) (15) (16) (17) (18) (19) . However, there was no threshold of serum 25(OH)D between 30 and 75 nmol/L that identified persons with abnormal concentrations of these analytes to justify the term vitamin D "insufficiency" as a signal of bone disease. A threshold was seen at 30 nmol/L, below which serum calcium was significantly lower and PTH and ALP were significantly higher. Although secondary hyperparathyroidism was evident in 34% of the 1439 participants with a serum 25(OH)D level of #30 nmol/L, hypocalcemia was found in only 6% of participants, and most individuals had no biochemical abnormalities even at levels ,30 nmol/L. For the bone parameters in the second cohort of 150 participants, no associations were detected between serum 25(OH)D and bone remodeling markers, aBMD, trabecular vBMD, or MMD. However, power analysis indicated that the number required to detect an association is at least 200. Therefore, our study lacked power to confirm the use of these concentrations of 25(OH)D as diagnostic labels to signal the presence of bone disease.
Measurements of calcium absorption and 1,25-dihydroxyvitamin D were not available. Need et al. The current study has several limitations. The data were cross-sectional. Information concerning disease status, calcium intake, and use of medications was not available in the Melbourne Pathology cohort, but the large sample size suggests the estimated mean values are likely to be robust. Whether the few individuals with a serum 25(OH)D of #30 nmol/L having biochemical abnormalities (6.1% with hypocalcemia, 3.4% with hypophosphatemia, and 6.1% with an elevated ALP) reflect underlying bone disease is not known. After exclusion of disease and medications that may influence bone, only a subset of the Austin Health cohort had available bone remodeling markers and measurements of bone microstructure; bone biopsy data were not available in this group. The small numbers of participants in the Austin Health cohort with serum 25(OH)D level of #30 nmol/L precludes identification of associations with abnormalities in bone material composition and (20) , thereby allowing analysis of the combined cohorts. We found seasonal variation in vitamin D and PTH, as has been reported in the literature (21) . However, seasonal adjustment did not alter the lack of association between vitamin D and aBMD/vBMD.
In summary, there is evidence of a vitamin D "deficiency" state when serum 25(OH)D is ,30 nmol/L. Secondary hyperparathyroidism was found in ;34% of participants, but even at this level, there was no evidence of secondary hyperparathyroidism in most individuals. No biochemical evidence was found to justify a designation of an "insufficiency" state when serum 25(OH)D levels were between 30 and 75 nmol/L.
We do not challenge the existence of a vitamin D deficiency state leading to osteomalacia. We do suggest that uncertainty remains as to the severity and duration of exposure below a level of 25(OH)D that produces effects on aBMD, bone microstructure, and MMD. We suggest that studies with more individuals are needed to evaluate these associations before a level of 25(OH)D can be designated as a marker of an "insufficiency" state. In the absence of this evidence, it remains unclear what benefit is derived from labeling individuals as having an insufficiency state or from initiating vitamin D supplementation.
In conclusion, it is difficult to justify a concentration of 75 nmol/L of 25(OH)D as a diagnostic threshold below which an insufficiency state exists. Signals do arise at the cutoff of 30 nmol/L in a subset of ;30% of individuals, thereby justifying the notion of a "deficiency" state with evidence of an increase in PTH. Nevertheless, even at this level, a substantial majority of individuals have no evidence of biochemical or structural abnormalities. We suggest that further work is needed to assemble a set of diagnostic criteria that more accurately signal the presence or impending abnormalities in biochemistry and bone morphology with high sensitivity and specificity so that individuals at low risk are not alarmed or overtreated.
